Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Rosacea Evolution

Rosacea Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Evolution and Treatment of Rosacea

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05815511
• Other study ID #: ROS.PROB
• Status: Recruiting
• Phase: N/A
• Start date: April 4, 2022
• Est. completion date: July 4, 2024

Study information

• Verified date: April 2023
• Source: Bionou Research, S.L.
• Contact: Laura Navarro Moratalla
• Phone: +34 865780170
• Email: laura.navarro[@]bioithas.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The clinical trial has a randomized, double-blind, placebo-controlled design, in which the aim is to evaluate the effect of a probiotic mix, with a 12-week treatment, on the evolution of rosacea.

This 12 weeks of treatment are structured into three visits: Visit 1 (initial; week 0), Visit 2 (intermediate; week 6) and Visit 3 (final; week 12).

Description:

The three visits that make up the study and the actions to be carried out in each of them are described below:

Visit 1 (initial; week 0)

Once the informed consent is signed, a doctor trained for the study performs the initial interview where it is verified that the patient meets all the inclusion criteria and none of the exclusion criteria and their medical history.The investigator will proceed to assign the patient the next study participant number and, according to a previously prepared randomization list, the treatment that they will receive during the study will be assigned.

The investigator will assess the severity and symptoms of rosacea according to the Investigator's Global Assessment (IGA) and Clinician Erythema Assessment (CEA) scales. The patient will also complete a questionnaire to assess the impact on quality of life due to the disease: Dermatology Life Quality Index (DLQI).

Visit 2 (intermediate; week 6)

In this intermediate visit, in addition to assessing the symptoms of the disease with the detailed scales, the investigator will record the adverse events reported by the patient, as well as the concomitant treatments used.

Also, the treatment compliance rate will be calculated by counting the capsules returned by the patient.

Visit 3 (final; week 12)

In the final visit, the same actions will be carried out as in the intermediate visit, evaluating the severity of the disease and the remaining capsules will be collected, to calculate treatment compliance, concomitant treatments and adverse events.

Visit 4 (post-treatment follow-up; week 24)

During this visit, the symptoms of the disease will be assessed with the two scales used in the study and the treatments that the patient has required during the 12 weeks after the end of the study treatment will be counted.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: July 4, 2024
• Est. primary completion date: April 4, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients of both sexes of an age equal to or greater than 18 years.

• Patients diagnosed with papulopustular rosacea with a minimum score of 2 points according to the Investigator's Global Assessment (IGA) index.

• Signature of informed consent by the patient

Exclusion Criteria:

• Pregnant, lactating, and/or women who do not agree to use an effective contraceptive method during the development of the study.

• Allergy and/or intolerance to any of the components of the product under study.

• Consumption of antibiotics in the previous two weeks.

• Consumption of probiotics in the previous two months.

• Isotretinoin use in the previous six months.

• Light procedures (IPL, laser, Kleresca) in the previous three months.

• Participation in other clinical studies in the previous two months.

• Other dermatological pathologies.

Related Conditions & MeSH terms

• Rosacea
• Rosacea, Papulopustular

Intervention

Dietary Supplement:
• Probiotic mixture
Oral capsule consumption once a day for 12 weeks
• Placebo
Oral capsule consumption once a day for 12 weeks

Locations

Country	Name	City	State
Spain	Eguren Dermatology and Aesthetics Clinic	Madrid
Spain	MiBioPath UCAM Research Group	Murcia
Spain	Salamanca University Hospital. Dermatology Service	Salamanca
Spain	Gavín Dermatologists Clinic	Vigo	Pontevedra

Sponsors (1)

Lead Sponsor	Collaborator
Bionou Research, S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of adverse events at 6 and 12 weeks	Adverse events reported by patients during follow-up at week 6 and week 12 visits are recorded	12 weeks
Primary	Changes from baseline in Investigator's Global Assessment (IGA) index score at 6, 12 and 24 weeks	IGA index measures the severity of rosacea; Score range is from 0 to 6 according to the severity of the disease; 0=clear; 1=minimum; 2=mild; 3=mild-moderate; 4=moderate; 5=moderate-severe; 6=severe	24 weeks
Secondary	Changes from baseline in Clinician Erythema Assessment (CEA) scale at 6, 12 and 24 weeks	CEA scale measures the severity of rosacea; Score range is from 0 to 4 according to the severity of the disease; 0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe	24 weeks
Secondary	Number of days using concomitant treatments during the 12 weeks of intervention	The number of days and the dose of concomitant treatments applied during the study will be counted, especially taking into account the consumption of: Doxycycline; Isotreninoin; Ivermectin	12 weeks
Secondary	Treatments used during the 12 weeks after completion of study treatment.	The number of days and the dose of treatments applied during the 12 weeks after completion the study will be counted	12 weeks
Secondary	Changes from baseline in Dermatology Life Quality Index (DLQI) at 6 and 12 weeks	DLQI measures the impact rosacea has on your quality of life; The index has 10 questions. Each question answered with "Very much" is counted with 3 points, "A lot" with 2, "Little" with 1, and "Not at all" as 0.; The score obtained can range between 0 and 30 points, this being the worst possible score.	12 weeks
Secondary	Study treatment compliance rate at 6 and 12 weeks.	The treatment adherence is collected, checking the number of remaining capsules in each of the visits	12 weeks